Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (GB:0VRQ)
LSE:0VRQ
RESEARCH TOOLSreports
Holding GB:0VRQ?
Track your performance easily
See the Price Targets and Ratings of:
0VRQ Analyst Ratings
Moderate Buy
10 Buy
6 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0VRQ Stock 12 Month Forecast
Average Price Target
$71.56
▲(46.73% Upside)
| Highest Price Target$105.00 | Average Price Target$71.56 | Lowest Price Target$30.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
Reiterated
10/18/24
RBC Capital
Reiterated
10/04/24
Morgan Stanley
Reiterated
08/08/24
JMP Securities
Reiterated
08/08/24
Oppenheimer
Assigned
08/06/24
Evercore ISI
Assigned
08/06/24
Barclays
Reiterated
08/06/24
William Blair
Reiterated
08/06/24
TD Cowen
Assigned
08/06/24
Needham
Reiterated
08/06/24
BMO Capital
$97
Buy
98.89%
Upside
Reiterated
08/06/24
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus
$60→$59
Hold
20.98%
Upside
Reiterated
08/06/24
Crispr Therapeutics price target lowered to $59 from $60 at StifelCrispr Therapeutics price target lowered to $59 from $60 at Stifel
Robert W. Baird
$52
Hold
6.62%
Upside
Reiterated
08/06/24
Crispr Therapeutics AG: A Cautious Hold Amidst Revenue Recognition Delays and Evolving CAR-T Pipeline
Piper Sandler
$105
Buy
115.30%
Upside
Reiterated
08/06/24
Crispr Therapeutics AG (CRSP) Receives a Buy from Piper Sandler
Chardan Capital
$112→$94
Buy
92.74%
Upside
Reiterated
08/05/24
Crispr Therapeutics price target lowered to $94 from $112 at ChardanCrispr Therapeutics price target lowered to $94 from $112 at Chardan
Best Analysts Covering Crispr Therapeutics AG
Which Analyst Should I Follow If I Want to Buy GB:0VRQ and Sell After:
1 Month
xxx
Success Rate
13/20 ratings generated profit
Average Return
+11.07%
assigned a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +11.07% per trade.
3 Months
xxx
Success Rate
22/37 ratings generated profit
Average Return
+14.97%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 59.46% of your transactions generating a profit, with an average return of +14.97% per trade.
1 Year
Success Rate
17/37 ratings generated profit
Average Return
+21.70%
reiterated a buy rating 3 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 45.95% of your transactions generating a profit, with an average return of +21.70% per trade.
2 Years
xxx
Success Rate
16/37 ratings generated profit
Average Return
+14.28%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 43.24% of your transactions generating a profit, with an average return of +14.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0VRQ Analyst Recommendation Trends
Rating
May 24
Jun 24
Jul 24
Aug 24
Oct 24
Strong Buy
12
14
11
10
8
Buy
7
7
4
4
3
Hold
5
6
6
7
7
Sell
1
1
2
3
3
Strong Sell
0
0
0
0
0
total
25
28
23
24
21
Each month's total comprises the sum of three months' worth of ratings.
0VRQ Financial Forecast
0VRQ Stock Forecast FAQ
What is GB:0VRQ’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics AG’s 12-month average price target is $71.56.
What is GB:0VRQ’s upside potential, based on the analysts’ average price target?
Crispr Therapeutics AG has 46.73% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Crispr Therapeutics AG a Buy, Sell or Hold?
Crispr Therapeutics AG has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 6 hold ratings and 2 sell ratings.
What is Crispr Therapeutics AG’s share price target?
The average share price target for Crispr Therapeutics AG is $71.56. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $105.00 ,and the lowest forecast is $30.00. The average share price target represents 46.73% Increase from the current price of $48.77.
The highest analyst share price target is $105.00 ,and the lowest forecast is $30.00. The average share price target represents 46.73% Increase from the current price of $48.77.
What do analysts say about Crispr Therapeutics AG?
Crispr Therapeutics AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of Crispr Therapeutics AG?
To buy shares of GB:0VRQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.